Beovu
Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration
February 18, 2020Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma
The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …
Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration
December 13, 2019Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma
Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
FDA approves Novartis’ Beovu injection for wet age-related macular degeneration
October 8, 2019Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma
Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
October 16, 2026
Sterling doubles ADC manufacturing capacity at Welsh facility
October 16, 2026
Femtosecond laser cuts lung tumour margin assessment time
October 15, 2026
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
October 15, 2026
